Plain-English translation of NCT06716996 on ClinicalTrials.gov ↗ · Source last updated · Translation generated ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a treatment called repetitive transcranial magnetic stimulation (rTMS) — a non-invasive procedure that uses magnetic pulses to gently stimulate the brain — to help reduce depression and severe fatigue in people who developed these symptoms after COVID-19 and haven't recovered. Researchers know that over 60 million people worldwide are dealing with persistent post-COVID symptoms, but there aren't many proven treatments available. This study will randomly assign participants to either receive the real treatment or a placebo treatment to see if the magnetic stimulation actually helps.
Many people continue to suffer from debilitating depression and exhaustion long after recovering from COVID-19, but doctors have few treatment options to offer them. This trial exists to find out whether this non-invasive brain stimulation technique — which has already been proven safe and effective for depression from other causes — could provide relief for post-COVID depression.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either 20 sessions of real magnetic brain stimulation or a placebo treatment that looks and feels the same. Before and after your treatment sessions, you'll complete detailed assessments of your mood and symptoms, and researchers will also take blood samples to study your immune system. The whole study involves several visits over a few weeks, but the individual magnetic stimulation sessions are quick and non-invasive — you sit in a chair while a magnetic coil is placed against your scalp.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Switzerland